story of the week
Effect of Combined Use of SGLT2 Inhibitors and Pioglitazone on the Risk of MASH in Individuals With Type 2 Diabetes
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Diabetes, Obesity & Metabolism
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Benefits of combining SGLT2 inhibitors and pioglitazone on risk of MASH in type 2 diabetes-A real-world study
Diabetes Obes Metab 2024 Nov 05;[EPub Ahead of Print], CH Lee, DT Lui, LY Mak, CH Fong, KS Chan, JH Mak, CY Cheung, WS Chow, YC Woo, MF Yuen, WK Seto, KS LamFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.